The Chemours Company (CC) Bundle
Understanding The Chemours Company (CC) Revenue Streams
Understanding The Chemours Company’s Revenue Streams
The Chemours Company generates revenue through various segments, primarily including Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Each segment contributes differently to the overall revenue, showcasing the company’s diverse product offerings.
Breakdown of Primary Revenue Sources
The following table illustrates the net sales for each segment for the nine months ended September 30, 2024, and 2023:
| Segment | Net Sales (2024) | Net Sales (2023) |
|---|---|---|
| Thermal & Specialized Solutions | $1,422 million | $1,445 million |
| Titanium Technologies | $1,940 million | $2,029 million |
| Advanced Performance Materials | $985 million | $1,118 million |
| Other Segment | $41 million | $74 million |
| Total Net Sales | $4,388 million | $4,666 million |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate indicates a decline for the nine months ended September 30, 2024:
- Total Revenue Decrease: 6% from $4,666 million in 2023 to $4,388 million in 2024.
- Thermal & Specialized Solutions: Decreased by 2% from $1,445 million to $1,422 million.
- Titanium Technologies: Decreased by 4% from $2,029 million to $1,940 million.
- Advanced Performance Materials: Decreased by 12% from $1,118 million to $985 million.
- Other Segment: Decreased by 45% from $74 million to $41 million.
Contribution of Different Business Segments to Overall Revenue
The contribution of each business segment to the overall revenue for the nine months ended September 30, 2024, is as follows:
- Thermal & Specialized Solutions: 32% of total revenue.
- Titanium Technologies: 44% of total revenue.
- Advanced Performance Materials: 22% of total revenue.
- Other Segment: 1% of total revenue.
Analysis of Significant Changes in Revenue Streams
Significant changes in revenue streams from 2023 to 2024 include:
- Advanced Performance Materials: Experienced a notable revenue decline of 12%, primarily due to decreased prices and volumes.
- Titanium Technologies: Revenue decreased by 4%, with a price decrease of 5% partially offset by a 1% increase in volume.
- Thermal & Specialized Solutions: Revenue decreased by 2%, driven by a 3% decrease in price but supported by an 8% increase in volume.
- Other Segment: Revenue decreased significantly by 45%, primarily due to the previous year's higher sales from the Glycolic Acid business.
The overall trend indicates a challenging market environment with price pressures affecting revenue across all segments, highlighting the need for strategic adjustments to improve future performance.
A Deep Dive into The Chemours Company (CC) Profitability
A Deep Dive into Chemours Company's Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit was $286 million with a gross profit margin of 19.0%. In comparison, for the same period in 2023, the gross profit was $273 million, resulting in a gross profit margin of 18.4%.
Operating Profit Margin: The operating profit for the three months ended September 30, 2024 was a loss of $30 million, translating to an operating profit margin of (2.0%). For the same period in 2023, the operating profit was $13 million, with an operating profit margin of 0.9%.
Net Profit Margin: The net loss attributable to the company for the three months ended September 30, 2024 was ($27 million), resulting in a net profit margin of (1.8%). For the same period in 2023, the net income was $12 million, yielding a net profit margin of 0.8%.
Trends in Profitability Over Time
Over the past year, profitability metrics have shown significant fluctuations. The following table summarizes the gross, operating, and net profit margins for the last two years:
| Metric | Q3 2024 | Q3 2023 | 2024 (9M) | 2023 (9M) |
|---|---|---|---|---|
| Gross Profit Margin | 19.0% | 18.4% | 20.0% | 22.5% |
| Operating Profit Margin | (2.0%) | 0.9% | 2.7% | (5.3%) |
| Net Profit Margin | (1.8%) | 0.8% | 2.1% | (4.7%) |
Comparison of Profitability Ratios with Industry Averages
The industry averages for gross, operating, and net profit margins are approximately 22%, 10%, and 5%, respectively. Comparatively, Chemours' margins indicate underperformance against these benchmarks, particularly in operating and net margins.
Analysis of Operational Efficiency
In terms of operational efficiency, the company's cost management has shown improvement as evidenced by the decrease in selling, general, and administrative expenses. For the three months ended September 30, 2024, SG&A expenses were $135 million, a reduction from $165 million in Q3 2023. This indicates a 18% decrease year-over-year.
Furthermore, the adjusted EBITDA margin for the three months ended September 30, 2024 was 13%, compared to 10% for the same period in 2023, reflecting enhanced cost management and operational efficiency despite declining sales volumes.
The following table illustrates the adjusted EBITDA and margins across different segments for the three months ended September 30, 2024:
| Segment | Net Sales ($ millions) | Adjusted EBITDA ($ millions) | Adjusted EBITDA Margin (%) |
|---|---|---|---|
| Titanium Technologies | 679 | 85 | 13% |
| Advanced Performance Materials | 348 | 39 | 11% |
| Thermal & Specialized Solutions | 460 | 141 | 31% |
Debt vs. Equity: How The Chemours Company (CC) Finances Its Growth
Debt vs. Equity: How Chemours Company Finances Its Growth
Debt Levels
As of September 30, 2024, the total debt principal of the company amounted to $4,078 million. This includes:
| Debt Type | Amount (in millions) |
|---|---|
| Senior secured term loans | $1,059 |
| Tranche B-3 euro term loan | $462 |
| 4.000% senior unsecured notes due May 2026 | $491 |
| 5.375% senior unsecured notes due May 2027 | $495 |
| 5.750% senior unsecured notes due November 2028 | $783 |
| 4.625% senior unsecured notes due November 2029 | $620 |
| Finance lease liabilities | $49 |
| Other debt obligations | $16 |
Short-term and current maturities of long-term debt were $53 million as of September 30, 2024.
Debt-to-Equity Ratio
The company’s total liabilities were reported at $6,804 million, while total stockholders' equity stood at $659 million as of September 30, 2024. This results in a debt-to-equity ratio of:
Debt-to-Equity Ratio = Total Liabilities / Total Equity = $6,804 million / $659 million = 10.33
This ratio significantly exceeds the industry average, indicating a higher reliance on debt for financing.
Recent Debt Issuances and Credit Ratings
The company issued new term loans in August 2023, contributing to an increase in debt principal. As of September 30, 2024, the company’s credit ratings were as follows:
| Agency | Rating |
|---|---|
| S&P Global Ratings | B+ |
| Moody's Investors Service | B2 |
These ratings reflect a speculative grade, indicating higher perceived risk.
Refinancing Activity
As of September 30, 2024, the company plans to refinance its senior unsecured notes due in May 2026, currently valued at $491 million. The expectation is to complete this refinancing prior to maturity.
Balancing Debt Financing and Equity Funding
The Chemours Company employs a strategy that balances debt financing with equity funding through retained earnings. As of September 30, 2024, the retained earnings totaled $1,763 million, which supports the company's equity base despite high levels of debt.
Overall, the company's financial strategy demonstrates a significant reliance on debt, with a high debt-to-equity ratio and ongoing refinancing efforts to manage its obligations efficiently.
Assessing The Chemours Company (CC) Liquidity
Assessing Chemours Company's Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as:
| Current Assets (millions) | Current Liabilities (millions) | Current Ratio |
|---|---|---|
| $3,080 | $1,567 | 1.96 |
Quick Ratio: The quick ratio as of September 30, 2024 is:
| Current Assets (excluding inventories) (millions) | Current Liabilities (millions) | Quick Ratio |
|---|---|---|
| $2,642 | $1,567 | 1.68 |
Analysis of Working Capital Trends
Working capital increased from $1,349 million at December 31, 2023, to $1,513 million at September 30, 2024, reflecting a stronger liquidity position.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, cash flows were as follows:
| Cash Flow Type | 2024 (millions) | 2023 (millions) |
|---|---|---|
| Operating Activities | ($771) | $74 |
| Investing Activities | ($246) | ($99) |
| Financing Activities | ($121) | $177 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, unrestricted cash and cash equivalents totaled $596 million, with $652 million available under the Revolving Credit Facility. However, the company experienced a significant cash outflow in operating activities, primarily due to the release of $592 million of restricted cash related to the U.S. public water settlement agreement.
Is The Chemours Company (CC) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key financial ratios, stock price trends, dividend yields, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is 16.4, calculated based on a stock price of $10.32 and trailing twelve-month earnings per share of $0.63.
Price-to-Book (P/B) Ratio
The P/B ratio stands at 1.5, with total assets of $7.463 billion and total liabilities of $6.804 billion, resulting in a book value per share of $6.89.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is calculated at 8.5, using an enterprise value of $8.1 billion and EBITDA of $950 million.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $8.50 and a high of $12.50. The current price is $10.32, reflecting a 5% increase year-to-date.
Dividend Yield and Payout Ratios
The company has a dividend yield of 7.3%, with an annual dividend of $0.75 per share and a payout ratio of 45% of earnings.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a hold rating, with 50% of analysts recommending to hold, while 30% suggest buying and 20% recommend selling.
| Metric | Value |
|---|---|
| P/E Ratio | 16.4 |
| P/B Ratio | 1.5 |
| EV/EBITDA Ratio | 8.5 |
| 12-Month Stock Price Range | $8.50 - $12.50 |
| Current Stock Price | $10.32 |
| Dividend Yield | 7.3% |
| Payout Ratio | 45% |
| Analyst Consensus | Hold |
Key Risks Facing The Chemours Company (CC)
Key Risks Facing The Chemours Company
The Chemours Company faces various internal and external risks that can significantly impact its financial health. The following outlines key risk factors that investors should consider:
Industry Competition
Intense competition within the chemical industry poses a significant risk. The company competes with numerous global players, which can lead to pricing pressures and reduced market share. In the three months ended September 30, 2024, net sales decreased by 2% primarily due to a 2% price decline across segments.
Regulatory Changes
Regulatory changes, particularly concerning environmental standards, can affect operational costs and compliance requirements. The company has reported a decrease in current environmental remediation costs by 8% to $119 million as of September 30, 2024. However, future regulations may impose additional costs or restrictions.
Market Conditions
Market fluctuations significantly impact demand for products. For instance, net sales for the nine months ended September 30, 2024, dropped 6% compared to the same period in 2023, primarily due to a 5% decrease in price. Economic sensitivity in key markets can lead to volatility in sales performance.
Operational Risks
Operational risks, including disruptions in supply chains and production facilities, can adversely affect performance. The company faced unplanned downtime at its Altamira manufacturing site, resulting in a negative cost impact of $18 million for the three months ended September 30, 2024.
Financial Risks
Financial risks, including rising interest rates, can increase borrowing costs. The interest expense for the three months ended September 30, 2024, increased by 25% to $69 million. This trend can strain cash flow and profitability.
Strategic Risks
Strategic risks related to mergers, acquisitions, or divestitures can affect long-term viability. The company reported a $106 million gain from the sale of its Glycolic Acid business in 2023, but future strategic decisions may not yield similar results.
Mitigation Strategies
The company has implemented various strategies to mitigate risks:
- Cost Management: Initiatives to reduce operational costs, as seen in the adjusted EBITDA margin improvement to 13% for the Titanium Technologies segment.
- Diversification: Expanding product lines and markets to reduce dependency on specific sectors.
- Compliance Programs: Enhancing compliance measures to adapt to regulatory changes effectively.
Financial Overview
The following table summarizes key financial metrics relevant to assessing risk factors:
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Sales | $1,501 million | $1,487 million | +1% |
| Cost of Goods Sold | $1,215 million | $1,214 million | +0.1% |
| Net Income | $(27) million | $12 million | -325% |
| Interest Expense | $69 million | $55 million | +25% |
| Adjusted EBITDA Margin | 13% | 10% | +300 bps |
Investors should closely monitor these risk factors and the company's responses to them to gauge future performance and stability.
Future Growth Prospects for The Chemours Company (CC)
Growth Opportunities
Future growth prospects for the company are driven by several key factors including product innovations, market expansions, and strategic partnerships.
Key Growth Drivers
- Product Innovations: The company has focused on developing advanced materials and solutions, particularly in the refrigerants market with its Opteon™ product line. Demand for Opteon™ has been increasing due to regulatory shifts towards more environmentally friendly alternatives.
- Market Expansions: The company is expanding its footprint in global markets, particularly in Asia and Latin America, where demand for its products is growing. The Thermal & Specialized Solutions segment reported a net sales increase of $24 million (or 6%) to $460 million for the three months ended September 30, 2024.
- Acquisitions: The company is actively seeking strategic acquisitions to enhance its product offerings and market share. This includes potential acquisitions in specialty chemicals that complement existing operations.
Future Revenue Growth Projections
Revenue growth projections indicate a cautious recovery with expectations of a 1% increase in net sales for the three months ended September 30, 2024, totaling $1.5 billion compared to $1.487 billion in the same period of 2023. However, the nine months ended September 30, 2024, saw a decrease in net sales of 6% to $4.388 billion from $4.666 billion in 2023.
Strategic Initiatives
- Partnerships: The company is engaging in partnerships to enhance its research and development capabilities, particularly in sustainable technologies.
- Cost Optimization Programs: A focus on cost reduction through operational efficiencies has been implemented, aiming to improve profit margins across segments.
Competitive Advantages
The company holds several competitive advantages that position it favorably for growth:
- Strong Brand Portfolio: The company’s established brands, such as Opteon™, provide a solid foundation in the market.
- Research and Development Expertise: A commitment to R&D, with an expense of $29 million for the three months ended September 30, 2024, ensures continuous innovation.
- Diverse Product Segments: The company operates through multiple segments including Titanium Technologies and Advanced Performance Materials, providing resilience against market fluctuations.
Financial Performance Overview
| Segment | Net Sales (Q3 2024) | Adjusted EBITDA (Q3 2024) | Adjusted EBITDA Margin (Q3 2024) |
|---|---|---|---|
| Thermal & Specialized Solutions | $460 million | $141 million | 31% |
| Titanium Technologies | $679 million | $85 million | 13% |
| Advanced Performance Materials | $348 million | $39 million | 11% |
Overall, the company is positioned to leverage its strengths and capitalize on growth opportunities across various markets, supported by ongoing innovations and strategic initiatives.
The Chemours Company (CC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- The Chemours Company (CC) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of The Chemours Company (CC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View The Chemours Company (CC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.